Aroa Biosurgery Ltd (AU:ARX)
ASX:ARX
Want to see AU:ARX full AI Analyst Report?
ARX Stock Chart & Stats
AU$0.53
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.53
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.38 - AU$0.80
Previous CloseN/A
Volume195.72K
Average Volume (3M)302.12K
Market Cap
AU$176.41M
Enterprise ValueAU$180.32M
Total Cash (Recent Filing)AU$20.71M
Total Debt (Recent Filing)AU$6.14M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
May 31, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding345,902,650
10 Day Avg. Volume330,836
30 Day Avg. Volume302,123
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)1.73
Price to Sales (P/S)1.90
P/FCF Ratio-25.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.16Price Target Upside118.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$115.42M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue expansion between 2024 and 2025 indicates expanding adoption of Aroa's ECM products across wound care and surgical repair. Durable top-line growth supports scale benefits, broader clinical penetration and underpins future margin and cash flow improvement if trends persist.
Balance Sheet StrengthA high equity ratio and low leverage provide financial flexibility to fund commercialization, R&D and absorb operating losses without immediate refinancing. This stability reduces bankruptcy risk and gives management runway to execute strategic initiatives over the medium term.
Improving Operating ProfitabilityConversion from negative to positive EBITDA alongside a strong gross margin signals improving unit economics and operational leverage. If maintained, this structural improvement supports sustainable margins as revenue scales and reduces reliance on external funding over the next several quarters.
Bears Say
Persistent Net LossesOngoing net losses erode retained earnings and produce a negative return on equity, limiting ability to generate shareholder returns. Continued losses constrain reinvestment capacity and may necessitate equity or debt financing, diluting holders or increasing leverage risk over time.
Negative Free Cash FlowSustained negative free cash flow means the business is not self-funding capex and growth investments, increasing dependence on external capital. This reduces financial flexibility and raises execution risk if capital markets tighten or financing costs rise over the medium term.
Revenue Concentration DriversBusiness reliance on procedure volumes and distributor channels creates structural exposure to utilization cycles and partner performance. Limited direct control over channel execution can slow penetration, compress margins and amplify downside during elective-care slowdowns or distributor disputes.
Aroa Biosurgery Ltd News
ARX FAQ
What was Aroa Biosurgery Ltd’s price range in the past 12 months?
Aroa Biosurgery Ltd lowest share price was AU$0.38 and its highest was AU$0.80 in the past 12 months.
What is Aroa Biosurgery Ltd’s market cap?
Aroa Biosurgery Ltd’s market cap is AU$176.41M.
When is Aroa Biosurgery Ltd’s upcoming earnings report date?
Aroa Biosurgery Ltd’s upcoming earnings report date is May 31, 2026 which is in 36 days.
How were Aroa Biosurgery Ltd’s earnings last quarter?
Aroa Biosurgery Ltd released its earnings results on Nov 25, 2025. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of AU$0.01 by -AU$0.013.
Is Aroa Biosurgery Ltd overvalued?
According to Wall Street analysts Aroa Biosurgery Ltd’s price is currently Undervalued.
Does Aroa Biosurgery Ltd pay dividends?
Aroa Biosurgery Ltd does not currently pay dividends.
What is Aroa Biosurgery Ltd’s EPS estimate?
Aroa Biosurgery Ltd’s EPS estimate is <0.01.
How many shares outstanding does Aroa Biosurgery Ltd have?
Aroa Biosurgery Ltd has 345,902,650 shares outstanding.
What happened to Aroa Biosurgery Ltd’s price movement after its last earnings report?
Aroa Biosurgery Ltd reported an EPS of -AU$0.003 in its last earnings report, missing expectations of AU$0.01. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Aroa Biosurgery Ltd?
Currently, no hedge funds are holding shares in AU:ARX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aroa Biosurgery Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.16 (118.87% Upside)
AU$1.16 (118.87% Upside)
Blogger Sentiment
Bullish
AU:ARX Sentiment 100%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.50%
12-Months-Change
Fundamentals
Return on Equity
-2.00%
Trailing 12-Months
Asset Growth
-1.71%
Trailing 12-Months
Company Description
Aroa Biosurgery Ltd
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
ARX Stock 12 Month Forecast
Average Price Target
AU$1.16
▲(118.87% Upside)
Technical Analysis
Polynovo
―
Cochlear
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---